Investors

Latest Financial Results

Q3 2021

Quarter Ended Sep 30, 2021

Company Info

Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced and synthetic psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems.

IR Contacts

Company

Mydecine Innovations Group Inc.
Suite 810 - 789 West Pender Street
Vancouver, BC V6C 1H2

Investor Relations

Morgan Kervitsky
Director of Marketing
Contact@mydecineinc.com